SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant volatility following a failed orbital insertion of its BlueBird-7 satellite, which was launched by Blue Origin. The community is heavily divided between panic-selling due to potential launch delays and long-term investors viewing the dip as a prime buying opportunity, focusing on the company's insurance coverage and upcoming launch schedule.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining significant community attention as investors position themselves for potential catalysts, including upcoming data at the AACR conference and ongoing anticipation regarding the Phase 3 REGAL trial's final events. While some community members are actively discussing a possible short squeeze and institutional positioning, others remain skeptical about clinical trial transparency and management strategy, keeping the stock in a highly debated, volatile position.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining significant traction as a top-tier quantum play, with investors increasingly focused on its strategic partnerships with NVIDIA and its growing portfolio of government and aerospace contracts. Community sentiment is largely bullish, with many focusing on the stock's potential for a short squeeze and its perceived undervaluation relative to other players in the quantum sector.

Sidus Space, Inc. is a space-as-a-service company. The firm focuses on commercial satellite design, manufacture, launch planning, mission operations and in-orbit support, and data collection with a vision to demonstrate space operations for new technologies, and deliver data and predictive analytics to both domestic and global customers. The company was founded by Carol M. Craig on July 17, 2012 and is headquartered in Merritt Island, FL.

Sidus Space Inc - Ordinary Shares - Class A

Sidus Space is trending due to a major expansion of its StarVault orbital data storage partnership with Lonestar, fueling heavy retail discussion about the company's long-term growth and potential for a parabolic breakout. Investors are actively debating the stock's high volatility, debating the impact of recent capital raises, and analyzing its position as a speculative play ahead of upcoming sector catalysts like the anticipated SpaceX IPO.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing intense volatility and community-driven speculation following reports of a U.S. executive order aimed at fast-tracking ibogaine research for veterans. Traders are actively debating whether the move is a sustainable catalyst for a triple-digit squeeze on its low-float structure or a classic 'buy the rumor, sell the news' event ripe for a sharp reversal.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following reports of a strategic partnership with Google to develop custom AI inference and memory processing chips, positioning the company as a key infrastructure player alongside Broadcom. While some investors remain cautious about the sustainability of the recent rally and potential index rebalancing volatility, the community is actively debating the stock's long-term growth trajectory in the data center and optical networking sectors.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors digest news of its strategic expansion into custom AI hardware through expanded partnerships with Broadcom and Anthropic. The market is actively debating the competitive implications of Google's memory-optimizing algorithms for the broader semiconductor sector and the company's long-term monetization potential through its AI ecosystem.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is currently at the center of intense debate following a dramatic price surge and subsequent collapse, with community members aggressively divided between those labeling it a blatant pump-and-dump scam and those speculating on potential rebounds or short squeezes. Discussions are heavily focused on the concentration of token supply, accusations of market manipulation, and the broader volatility of speculative crypto assets, with many participants warning others to avoid the 'falling knife' while some still hunt for entry points.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors in SOXS are expressing intense frustration as the fund continues to slide despite ongoing geopolitical tensions and volatility in the semiconductor sector. The community is heavily focused on the rapid ascent of the underlying index, with many debating whether the current market momentum is a sustainable rally or a bubble-like blow-off top that will eventually trigger a sharp reversal.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently in the spotlight as investors anticipate key clinical data releases, with sentiment fueled by broader policy shifts and administrative support for accelerating psychedelic research. Community members are actively debating the company's competitive positioning, clinical trial progress, and the potential for a favorable regulatory landscape for mental health treatments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Brokerages

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been given a consensus rating of "Buy" by the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One...

Wall Street Zen Upgrades Spyre Therapeutics (NASDAQ:SYRE) to "Hold"

Wall Street Zen upgraded shares of Spyre Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $95.00 at JonesTrading

JonesTrading increased their target price on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the company a "buy" rating in a research report on Friday...

Top Biotech Stocks To Watch Today - April 16th

Danaher, Vertex Pharmaceuticals, argenex, Moderna, United Therapeutics, Capstone Therapeutics, and Spyre Therapeutics are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that develop, manufacture, or comm...

Spyre Therapeutics (NASDAQ:SYRE) Sees Large Volume Increase on Analyst Upgrade

Spyre Therapeutics (NASDAQ:SYRE) Sees Strong Trading Volume After Analyst Upgrade...

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up After Analyst Upgrade

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade...

Robert W. Baird Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Robert W. Baird increased their price objective on shares of Spyre Therapeutics from $65.00 to $90.00 and gave the company an "outperform" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>Spyre is looking forward to developing the drug as a single treatment, as well as in combination with its investigational antibodies SPY002 or SPY003.</li><li>TD Cowen says Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001.</li><li>Leerink continues to view the trial data as a best-case outcome for SPY00, one which derisks both its potential as a monotherapy and backbone in future combination regimens.</li></ul>Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data, with several noting the company’s experimental drug’s potential against Takeda’s Entyvio.The stock marked its highest single-day gain on Monday since June 2023.Earlier in the day, Spyre announced positive data from part A of its phase 2 trial of SPY001 in the treatment of moderate-to-severely active ulcerative colitis. The company said that the trial met its primary endpoint of statistically significant reduction in disease activity.The drug was further well tolerated though six subjects experienced treatment-emergent adverse events, including a serious event which the company deems as not related to the drug.Spyre is looking forward to developing the drug as a single treatment as well as in combination with its investigational antibodies SPY002 or SPY003.<h2 class="st-heading-2">Analyst Take Away</h2>TD Cowen said Spyre Therapeutics' data "strengthened our confidence in an already great dataset" for SPY001. The firm has a ‘Buy’ rating on Spyre.Wedbush analyst David Nierengarten, meanwhile, raised the firm's price target on Spyre to $80 from $65 and kept an ‘Outperform’ rating on the shares. Spyre's SPY001 monotherapy surpassed historical benchmarks for Takeda's (TAK) Entyvio with 40% clinical remission and 51% endoscopic improvement, yielding an anticipated upside scenario, the analyst told investors in a research note.Leerink, which also has an ‘Outperform’ rating on the stock, raised the firm's price target on Spyre Therapeutics to $106 from $49. Leerink continues to view the trial data as a best-case outcome for SPY001, one which derisks both its potential as a monotherapy and backbone in future combination regimens. The target change reflects the firm's increased conviction and higher probability of success for SPY001 opportunities in UC and Crohn's disease, it said.Overall, the firm believes these "striking initial” study results represent best case data for SPY001, suggesting positively differentiated efficacy vs. Entyvio across a broad range of objective and symptomatic measures. The data position SPY001 as a leading agent in this multi-billion-dollar class, argues Leerink.Stoked by the data, BTIG analyst Julian Harrison also raised the firm's price target on Spyre to $98 from $70, and kept a ‘Buy’ rating on the shares while raising the firm's view of the odds of success for SPY001 combos in UC to 80% following the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around SYRE stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/SYRE">SYRE stock</a> has gained nearly 400% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/eras-stock-slumps-against-rvmd-rally-analyst-stays-bullish/cZJ8IHGRIuH">ERAS Stock Slumps Against RVMD Rally — Analyst Stays Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Shares of Spyre Therapeutics Inc. (SYRE) closed up 23% on Monday after several analysts upped their price targets on the stock on the heels of positive ulcerative colitis trial data

Equity

Earlier in the day, Spyre said that part of its phase 2 ulcerative colitis trial met its primary endpoint of statistically significant reduction in disease activity.


Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $106.00

Leerink Partners raised their price objective on Spyre Therapeutics from $49.00 to $106.00 and gave the company an "outperform" rating in a research note on Monday...

Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug

Spyre Therapeutics stock jumps after Phase 2 SKYLINE data; SPY001 shows efficacy in ulcerative colitis as analysts maintain bullish outlook.read more...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.67	--	--	N/A
Q4 '25	-$0.71	-$0.70	1.30%	BEAT
Q3 '25	-$0.76	-$0.15	80.28%	BEAT
Q2 '25	-$0.75	-$0.49	34.98%	BEAT
Q1 '25	-$0.84	-$0.60	28.66%	BEAT

SYRE
Spyre Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest SYRE News

SYRESpyre Therapeutics Inc